AIRS Medical, a prominent developer of artificial intelligence (AI) solutions for medical imaging, has announced a significant strategic growth investment from TA Associates, a leading global private equity firm. The capital injection is intended to propel AIRS Medical's international expansion, advance its AI-powered radiology technology, and drive ongoing product innovation within the medical imaging sector.
Founded in 2018, AIRS Medical specialises in AI-native magnetic resonance imaging (MRI) acceleration and reconstruction software. These solutions are engineered to enhance MRI scan speed, improve image quality, and streamline workflow performance for healthcare providers. The company's technologies are already widely adopted, serving over 1,700 healthcare institutions across more than 40 countries, with its AI tools utilised in over 6 million MRI examinations annually.
The investment comes as healthcare systems worldwide grapple with increasing demand for imaging services and often limited capacity. AIRS Medical's offerings, including its AI-powered MRI acceleration and image enhancement solution, SwiftMR®, and its MRI quantification and structured reporting platform, SwiftSight®, aim to address these challenges by providing a unified solution from image acquisition to clinical interpretation.
Dr. Hyeseong Lee, Co-Founder and Chairman of AIRS Medical, highlighted the ongoing struggle of many providers with growing imaging demand and capacity constraints, despite MRI scanners being highly valuable assets. He expressed enthusiasm for the partnership with TA Associates, stating it would further their mission to enhance accessibility to advanced diagnostics globally. Jason Park, CEO of AIRS Medical, added that the collaboration would accelerate product innovation and expand their international presence, helping healthcare providers extract greater value from existing MRI infrastructure.
While the specific financial terms of the transaction were not disclosed, the deal is anticipated to conclude in the second quarter of 2026, subject to standard closing conditions. This strategic investment underscores the growing confidence in AI's transformative potential within the healthcare sector, particularly in improving operational efficiency and patient outcomes.
Edward Sippel, Managing Director and head of TA Asia Pacific, emphasised AIRS Medical's differentiated AI platform, which addresses critical capacity and workflow challenges for radiology providers globally. Michele Lim, Senior Vice President at TA, noted TA's history of partnering with innovative healthcare technology companies to deliver better patient outcomes, expressing excitement for the collaboration with AIRS Medical.